Neuroblastoma Integrins by Young, Shanique A. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 9
Neuroblastoma Integrins
Shanique A. Young, Ryon Graf and
Dwayne G. Stupack
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55991
1. Introduction
In the body, cells are surrounded and supported by an intricate network of glycoproteins and
proteoglycans that make up a complex extracellular matrix, or ECM. Many constituents, such
as collagen, laminin, and fibronectin, are locally produced within the tissues, where they act
as physical scaffolds, growth factor depots, and points of anchorage [1]. The local rigidity and
composition of the matrix also provide environmental cues that govern cell behavior.
The ECM surrounding cells can be considered in two broad classes. On one hand, there exists
a ‘physiologic’ ECM, present in all tissues, that aids in structuring and maintaining homeo‐
stasis. Typical ECM components include several collagens and laminins, as well as proteogly‐
cans. On the other hand, there is a provisional ECM that is deposited during wounding,
hemostasis and tissue remodeling. This ECM is typically deposited, digested and replaced in
a very dynamic manner, and contains proteins such as fibronectin, fibrin, vitronectin and even
residual fragments of collagen and laminin. This type of ECM promotes tissue remodeling as
well as cellular survival, proliferation and invasion. In both types of ECM, however, the
diversity in the type and quantity of each individual ECM component present determines the
physical properties of these tissues. In so doing, this modulates the mechanical forces sensed
by cells that bind to the ECM, and provides yet another layer of information relayed to cells.
This ‘mechanosensation’ requires integrins, receptors that can transmit extracellular forces to
the actin cytoskeleton.
Although many classes of receptors can interact with components of the ECM, the integrins
are regarded as the principle receptors mediating anchorage and attachment to the ECM [2].
The name integrin was derived from initial observations that these receptors permitted a
realignment of the actin cytoskeleton to match that of an underlying ECM. Integrins are
transmembrane glycoprotein receptors that are composed of a heterodimer of α and β subunits
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[3]. There are 18 different α subunits and 8 β subunits, but there are a limited number of possible
combinations that can form from these subunits. To date, at least 24 unique integrin complexes
have been identified, each with its own binding specificity for different subsets of ligands
(Figure 1). Cells will generally express only a limited number of integrins, perhaps 10 of these
combinations. The particular repertoire of integrins expressed by a given cell varies, but is
typically closely tied to a cell’s particular extracellular microenvironment. Differences in
integrin binding to a ligand can be subtle. For example, approximately one third of human
integrins bind to an arginine-glycine-aspartic acid (RGD) sequence of amino acid residues, but
this can be profoundly conformation specific, and thus not all ‘RGD-binding’ integrins are
capable of binding all RGD sequences with appreciable affinity.
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Figure 1. Integrin heterodimers and their ligands This diagram shows the 24 known heterodimers and their li‐
gands. Integrin heterodimers are represented by an α and a β subunit connected by a black line. For example, the β1
subunit dimerizes with 12 different α subunits. The ligands for each heterodimer are written in purple.
1.1. Integrin structure
Each integrin is composed of a large extracellular region of 600-1000 amino acids, as well as a
single transmembrane domain. The extracellular regions can be broadly thought of in terms
of a head and stalk (leg/thigh) region; the head is the critical site for ligand binding and divalent
cation binding, as well as heterodimerization between the α and β subunits. Most integrins
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also have a small (~30-50 amino acid) cytosolic domain, with the singular exception being
integrin β4, which has a large cytosolic domain that interacts with intermediate filaments [4].
Integrins are cysteine–rich proteins, and have extensive crosslinking within domains that
stabilize domain structure. Thus, integrins appear at different sizes when analyzed on reducing
and non-reducing gels, and detection of integrins by some antibodies may require either
condition, depending upon the linearity or conformation dependence of an epitope.
The integrin extracellular domains are required for and sufficient to bind to ECM or to
‘receptor-ligands’ present on the surface of adjacent cells. However, the binding of integrins
to their ligands is controlled by their conformation, which is influenced by the stalk and
cytosolic regions of the molecule. Inactive integrins adapt a ‘folded back’ conformation at a
region halfway up the stalk (at the ‘genou,’ or knee, between the thigh and leg). Active integrins
are extended molecules with stalks separated, and intermediates between these states tend to
have intermediate affinities for ligands. Integrin-ligand binding requires the presence of
divalent cations, with a typical preference for manganese, magnesium and calcium, although
the relative preference for optimal affinity varies among the different heterodimers. These
divalent cations, and Mn+2 in particular, directly influence integrin conformation, stabilizing
them in the extended and high affinity conformation (Figure 2).
With the exception of circulating hematopoietic cells, which tend to maintain their integrins
in an inactive conformation, most cells that have been examined express both active and
inactive integrins. Active integrins tend to form higher order clusters on the cell surface, which
promotes their localization to sites of ligation. There, the integrins are further stabilized by
interaction with ligand. The accumulation of integrins in these sites creates a ‘Velcro-like’
effect, with groups of integrins (rather than individual molecules) collaborating to strengthen
anchorage and to induce downstream signaling points of extracellular matrix contact. This
clustering effect is called integrin ‘avidity’ regulation, which is distinct from affinity. This
permits the stable interaction with the ECM required for sustained cellular anchorage and
signaling via the assembly of a ‘focal adhesion complex’ that accumulates proximal to the
membrane.
The focal adhesion complex that forms is multifunctional, and is capable of signaling directly,
scaffolding additional or alternative signals, and engaging the actin/myosin system. Thus,
despite the absence of intrinsic kinase or proteolytic activity, integrins transform mechanical
and chemical cues from the extracellular environment into intracellular signals that profound‐
ly impact cell behavior and function.
The focal adhesion complex contains a complicated array of non-receptor kinases and adaptor
proteins that mediate downstream signaling events. As will be discussed in more detail below,
integrin effectors in the focal adhesion include diverse signaling elements such as: focal
adhesion kinase (FAK), src kinase, cytoskeletal elements including talin, paxillin and vinculin,
phosphoinositide 3 kinase, and small GTPases of the Ras and Rho families and their effectors
[5, 6]. Importantly, as part of the clustering process, integrins tend to undergo lateral associa‐
tions with other cell surface receptors such as the receptor tyrosine kinases, EGFR and VEGFR,
which are important for other global cellular signaling events. This type of signaling, in which
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the integrin ectodomain is ligated and transforms information from the extracellular environ‐
ment into cues for cytosolic signaling events has been termed “outside-in signaling.”
However, in some cases, signals from inside the cell result in changes in integrin conformation.
These are typically associated with cytosolic proteins binding to the cytosolic domains of the
integrins. This type of regulation of integrin conformation is called “inside-out signaling.” Both
types of signaling are important for understanding the role of integrins in normal tissues and
in disease pathology.
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Figure 2. Integrin structure and activation Integrins are composed of a large extracellular domain and short intra‐
cellular tails (with the exception of the β4 tail). The extracellular domain comprises a head region and a stalk region,
which includes the “thigh” and “leg” areas of the integrin. Ligand binding occurs at the head region and requires the
presence of divalent cations such as manganese, magnesium, and calcium. Integrins on the cell surface can exist in a
range of conformations that affect their affinity for ligand. In the low affinity conformation, the extracellular domain is
folded back at the knee (between the thigh and leg areas) and the intracellular tails are clasped together. In the high
affinity conformation the extracellular stalk is straight, the subunits are slightly separated and the tails shift apart as
well. Conformations between these low and high affinity states confer intermediate affinity for ligand. Changes in
conformation can be regulated by intracellular signaling events such as the binding of cytosolic proteins to integrin
tails leading to integrin clustering, focal adhesion formation and further interaction of cytoskeletal proteins.
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2. Integrins and development
2.1. Integrins in early development
The ability of cells to interact with their extracellular environment is crucial for most devel‐
opmental processes. Consequently, it is perhaps not surprising that integrins, as mediators of
the interplay between cells, the ECM and the microenvironment, have critical roles in early
development. The early physiological relevance is evident in defects observed in murine
genetic models lacking proper integrin function or expression. Overall, the loss of the β1, α5,
and α4 subunits leads to an embryonic lethal phenotype. The loss of the αv or α3 subunits
permits initial and subsequent development, but results in perinatal lethality. Other integrin
subunits do not appear to be essential during development.
Nonetheless, loss, misregulation, or improper function of integrins can lead to other abnor‐
malities [7]. (Table 1)
2.2. Integrins in nervous system development
The development of the nervous system is dependent on integrin function, in part, because it
involves extensive migration of neuronal precursors which is mediated by integrins. During
the process of neurulation, the neural crest forms in the region of the neural plate border. Upon
formation of the neural tube, neural crest cells undergo an ‘epithelial-to-mesenchymal-like
transition’ which permits them to move along migratory tracks. These tracks lead cells to a
variety of destinations where they differentiate and help to form several different tissue types.
During development, collagens, laminins, fibronectin and vitronectin are expressed along
these migratory pathways [28]. Disruption of integrin-ligand binding inhibits neural crest cell
migration and results in impaired function in the peripheral nervous system. Following the
initial gross exodus of neurons from the neural crest, integrins also play other key roles in the
development of the peripheral nervous system, including the establishment of Schwann cell
polarity [29], neurite outgrowth [30, 31] and myelination [32].
In addition to the requirement for integrins to support migration, integrins are also important
for arresting migration at the proper time and place. In the central nervous system, for example,
the presence of the α6 and β1 subunits appears to serves as stop signals for neuronal cells when
they reach a laminin rich region. This is critical for cortical plate formation. In the absence of
these integrins, neuronal precursors migrating outward to the outermost layer of the cortical
plate overshoot their destination and disrupt the cortical plate structure [33, 34].
2.3. Integrin expression in the dorsal root ganglion and in neuroblasts
Neuroblastoma is a tumor that is considered to arise from ganglion or pre-ganglion cells. To
begin to understand the pathological roles of integrins in this disease, it is helpful to be familiar
with the normal expression patterns of these receptors in neural crest cells and how that
expression changes over time. Neural crest cells express subsets of integrins that allow them
to adhere to the fibrillar proteins that line their migratory pathways. Truncal neural crest cells,
which give rise to dorsal root ganglia, sympathetic ganglia, and the adrenal medulla express
Neuroblastoma Integrins
http://dx.doi.org/10.5772/55991
193
receptors for vitronectin (αvβ1, αvβ3, and αvβ5: [35]), laminin (α1β1, α3β1,: [36] [37]), and
fibronectin and associated molecules (α4β1, α5β1, α8β1, αvβ1 and β8 integrin: [37], [38].
Antibody blockade of any one type of these integrins is unable to completely abolish cell
migration, consistent with a multi-receptor and complex ligand system. However, in studies
on avian truncal neural crest cells, the α3β1, α4β1, and αv integrins appear to be the most
crucial to maintain migration [38]. In particular, inhibition of the interaction between α4β1 and
Integrin subunit Genetic Defect (KO) Expressed on NB
tumors
Notes
α1 Viable Yes Normal; [8]
α2 Viable Yes Abnormal mammary branching
morphogenesis; [9]
α3 Perinatal lethality Yes Abnormal kidneys; [10]
α4 Lethal, by E14.5 Yes Abnormal placenta and heart formation;
[11]
α5 Lethal, E11 Yes Abnormal mesoderm morphogenesis; [12]
α6 Perinatal lethality Yes Skin blistering; [13]
α7 Viable Yes Muscular dystrophy; [14]
α8 Perinatal lethality No* Abnormal kidneys and lungs; [15, 16]
α9 Perinatal lethality No Bilateral chylothorax; [17]
α10 Viable No Improper function of growth plate
chondrocytes; [18]
α11 Viable No Dwarfism; [18]
αv Perinatal lethality Yes Brain and bladder, hemorrhages; [19]
αL Viable No Impaired leukocyte recruitment; [18]
αM Viable No Impaired phagocytosis; obesity; [18]
αE Viable No Inflammatory skin lesions; [18]
αIIb Viable No Impaired platelet aggregation; [18]
β1 Lethal, E5.5 Yes Abnormal mesoderm morphogenesis; [20]
β2 Viable No Impaired leukocyte recruitment; [21]
β3 Viable Yes Glanzmann’s thrombasthenia;
osteosclerotic; [22]
β4 Perinatal lethality No Skin blistering; [23]
β5 Viable Yes No apparent phenotype; [24]
β6 Viable No Macrophage infiltration in skin and lungs;
[25]
β7 Viable No No gut-associated lymphoid tissue; [26]
β8 Lethal, E12 - birth No* Abnormal placenta; defects in
neurovascular homeostasis; [27]
*Subunit found on neural crest cells but not yet reported on NB tumor cells
Table 1. Effects of Integrin Deletion in Murine Models
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its ligands via blocking antibodies or ligand-mimicking peptides, leads to a marked reduction
in neural crest cell migration [37].
As neural crest cells reach their target tissues and differentiate, their integrin expression
changes. For example, neural crest cells do not express detectable levels of α6β1 until they
differentiate into a peripheral nervous system cell type such as a Schwann cell precursor [39].
Conversely, neural crest cells express α1β1 but Schwann cell precursors do not [40, 41]. This
induction of expression of one class of integrins while another is eliminated is not well
understood, however, and further study will be required to elucidate additional neuroblast-
specific integrin expression and function.
2.4. Integrins in vascular system development
Similarly, the formation of the vascular system relies heavily on integrin function. During
vasculogenesis, or de novo formation of blood vessels, and angiogenesis, the growth of new
vessels from pre-existing vasculature, integrins play essential roles in endothelial cell migra‐
tion, adhesion to basement membranes and cell survival. Endothelial cells are known to
express a large number of β1 integrin heterodimers including the α1 through α6 subunits as
well as integrins α6β4, αvβ5, and αvβ3. The expression of different subsets of these integrins
is dependent on the activation state of the endothelial cells. For example, integrins αvβ3 and
α4β1 are primarily expressed on activated or angiogenic endothelial cells [42]. Knockout of
integrin αv leads to perinatal lethality due to vessel malformation [15] and studies on the αvβ3
heterodimer show that it is essential for the survival of angiogenic endothelial cells [43]. In
addition, knock-out of integrin α4 in mice is embryonic lethal by day 14.5 due to placental and
cardiac defects [11], likely due to a lack of binding to the α4 ligand, vascular cell adhesion
molecule-1 (VCAM-1) which is present on endothelial and smooth muscle cells.
The formation of the vasculature, and angiogenesis in particular, is of interest to scientists who
study neuroblastoma, which is typically a highly angiogenic disease. Although a focus has
been placed on the roles of integrins in development of the neuronal and vascular systems, the
ability of integrins to regulate such a large array of cellular functions renders them essential
for most, if not all, developmental processes. Their roles may be directly associated with their
adhesion and motility-related functions, or with the ability of integrins to indirectly enhance
the efficiency of other signaling pathways [44].
3. Integrin expression during tumorigenesis and tumor progression
3.1. Tumors exploit integrins for local invasion
As cells are transformed from a normal to malignant state, their integrin expression is
modulated to support pathologic behaviors. In primary tumors, integrin signaling can impact
cell growth, differentiation, and vascular infiltration and continues to be important as the
cancer progresses through the stages of metastasis (Figure 3). The initial steps of the metastatic
process involve the degradation and remodeling of extracellular matrix adjacent to primary
Neuroblastoma Integrins
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tumor cells, facilitating cancer cell migration into recruited blood vessels. This process is
termed local invasion. Usually, for local invasion to begin, cells from the primary tumor shift
from an epithelial or non-motile to a more mesenchymal phenotype. In addition, cells
frequently create a pathway for themselves by inducing degradation of the matrix via enzymes
such as matrix metalloproteases [45]. Integrins can regulate MMP expression and/or activity.
For example, integrin α2β1 is a positive regulator of MMP-1 expression [46, 47].
1. Cell Survival
2. Proliferation &
Growth Factor
Signaling
3. Tumor
Angiogenesis
5. Cell Invasion
& Intravasation
6. Embolization
7. Extravasation
4. Matrix Degradation
Figure 3. Roles Played by integrins in cancer progression Integrins play key roles in each phase of cancer progres‐
sion. 1. Ligation of integrins promotes cell survival 2. Co-signaling with growth factor receptors impacts cell prolifera‐
tion 3. Endothelial cell integrins are important for tumor angiogenesis 4. Integrins modulate the expression of
proteolytic enzymes such as matrix metalloproteinases, which play a role in matrix degradation during tumor cell inva‐
sion 5. Integrins are required for migration during invasion and binding to endothelial cells during intravasation (entry
into the vasculature) 6. In circulation, tumor cells interact with platelets and leukocytes via integrins and form cell em‐
boli that can lodge in capillary beds of distant tissues 7. Binding of tumor cell integrins such as α4β1 to endothelial
VCAM-1 can then promote extravasation of tumor cells into surrounding tissues.
3.2. Integrins, tumor metastasis, and tissue tropism
For many types of cancer, metastasizing cells spread to a specific subset of secondary locations
for establishment of metastatic nodules. This phenomenon, termed tissue tropism, has
historically been explained by two major theories. The “seed and soil” hypothesis proposed
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by Stephen Paget in 1889 followed his observation of tissue-specific patterns of tumor meta‐
stasis in 735 breast cancer patients. Paget noted that the pattern of organs bearing metastases
was not random, and suggested that certain tumor types preferentially metastasized to
compatible environments [48]. He proposed that ‘seeds’ of tumors required compatible ‘soil’
to take root and grow. An alternative theory, by Ewing, suggests that tissue tropism is simply
due to mechanical forces and circulatory patterns [49], and that tissue tropism results from
this. These are not absolutely exclusive theories, and it is reasonable that blood flow patterns
are important for the initial distribution of circulating tumor cells, while the propensity to
invade, grow and survive may be dependent on the presence of the appropriate integrin
ligands as well as other pro-survival factors.
Though there have been no studies specifically linking integrins to site-specific metastasis in
neuroblastoma, integrins have been shown to play a role in tissue tropism. The primary sites
of neuroblastoma metastasis are bone marrow, bone, lymph node and liver. In general, certain
integrins have been linked to metastasis to these sites. For instance, integrin α4β1 can promote
homing to the bone [50] and has been shown to enhance bone metastasis in melanoma [51].
This effect may be due to expression of VCAM-1 on bone marrow stromal cells. Integrin α4β1
may also promote lymphatic metastasis by enhancing binding to VCAM-1 present on lym‐
phatic endothelial cells [52]. Integrin α2β1 is associated with enhanced liver metastasis. This
is potentially due to its binding to collagen type IV expressed in liver sinusoids [53].
3.3. Indirect roles for integrins in metastasis
Since the metastatic cascade involves several steps, including local tumor invasion, intrava‐
sation, survival in the lymphatics/blood stream, extravasation, invasion into the new tissue
parenchyma and growth and establishment of metastatic nodules, there are many opportuni‐
ties for integrins to facilitate this process. The role of integrins in local invasion is clear. Once
cells gain entry into the vasculature, integrins are important for cell-cell and cell-platelet
adhesion leading to increased formation of cell emboli [54] and subsequent lodging in capillary
beds. Integrins are also important for the endothelial transmigration that follows. At the site
of distant metastasis, the microenvironment and composition of the extracellular matrix may
be different from that of the native tissue of the invading tumor cells. Here, the balance of
ligated and unligated integrins impacts cell behavior and survival, as discussed in Section 4.
The shedding of gangliosides also impacts neuroblastoma metastasis. Gangliosides are
glycosphingolipids with one or more sialic acids linked to them. In circulation, gangliosides
are associated with lipoproteins. There are several different types of gangliosides that are
classified based on the number of associated sialic acids. Some of these gangliosides, such as
GM3, are normally present in circulation. Conversely, elevated levels of circulating GD2, a
disialoganglioside, have been found in neuroblastoma patients and its concentration is
inversely related to progression-free survival. Shedding of gangliosides enhances integrin
α2β1-dependent platelet activation, leading to platelet aggregation, and increased adhesion
to vascular basement membranes [55]. These events can enhance tumor cell embolization
impacting the occurrence of cells lodging in capillary beds and invading into surrounding
tissue.
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Finally, it is worth noting that at any phase of tumor progression, cancer cells must evade the
immune system. Some T-cell lysis mechanisms are dependent on integrin expression. For
instance, binding of T-cell integrin LFA-1 (αLβ2) to its ligands ICAM-1 on tumor cells is
important in CD3-mediated T-cell lysis [56, 57]. Of note, ICAM expression on neuroblastoma
cells is associated with increased susceptibility to lymphokine-activated killer (LAK) cell lysis
following interferon gamma treatment [58].
3.4. Trends in integrin expression with neuroblastoma stage and grade
Since integrins impact cell differentiation and invasion, there has been an interest in linking
the expression of subsets of integrins with a particular tumor stage, or more appropriately,
with tumor ‘risk.’ Key risk predictors to date have been established by the Children’s Oncology
Group, and include status of the MYCN gene, the pathology of the tumor according to
guidelines established by Shimada [59], and in some cases the relative ploidy of the tumor.
Since integrins are associated with neuronal cell developmental stages and activities, it is
reasonable that integrin expression could offer insights into tumor activities.
In pioneering studies, using 45 clinical samples, Favrot et al. showed that the α2 and α6
subunits were associated with low grade, well-differentiated neuroblastoma samples. The
finding is consistent with observations of normal ‘neural crest cell to neuronal’ differentiation.
The β1 subunit was expressed on all samples while the α5 subunit was not expressed on any
samples examined. Samples expressing the α4, αv, β3, and β4 subunits revealed no N-Myc
amplification, and were associated with a good prognosis. In addition, expression of α4 and
β4 subunits was found selectively on Schwannian stromal cells [60].
Conversely, more recent studies have found that many neuroblastoma cell lines express
integrin α4 and that α4 expression is associated with increased tumor stage (stages 3 and 4) in
clinical samples [61]. At least on cell lines, integrin α5β1 also appears to be expressed [45] and
integrin αvβ3 has been described to be present on some malignant neuroblastomas [62]. In
addition, by flow cytometry, our lab consistently observes low levels of integrin αvβ5 on
established neuroblastoma cell lines, although whether this is a tissue culture adaptation or
reflects actual expression in situ remains unclear. Indeed, neuroblasts exhibit significant
plasticity, and although integrins may be associated with specific stages of neuroblastoma, or
specific developmental states where transformation of the neuroblast initially occurred, an
alternative hypothesis is that neuroblastoma may retain the capacity to alter their relative
integrin expression, and that this type of plasticity may itself be a malignancy factor.
Neuroblastomas fall into three common morphological/adhesive categories when grown in
vitro: S (Substrate adherent), N (Neuroblastic), and I (Intermediate) types [63, 64]. These
different types are sometimes ascribed to a particular cell line, though in many cases a cell line
may contain cells of all three types. Studies using tissue culture cell lines have shown that,
relative to S-type, N-type neuroblastomas exhibit decreased expression of β1 integrin and
greater expression of αvβ3, and are more migratory in vitro. However, the expression of αvβ3
on these cells is still relatively low, at least when one compares with tissues well known to
express αvβ3, such as angiogenic endothelium or melanoma. N-type cells also form more
colonies in soft agar and are more tumorigenic when implanted in mice than S-type, which are
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rarely able to form xenograft tumors [65]. S-type cells express fibronectin; it is therefore not
surprising that they represent the group of neuroblastoma that express α5β1integrin, the
fibronectin receptor [66].
The third type of cells is the ‘intermediate cells.’ Noted as potential ‘cancer stem cells’ as early
as 1989 by Ross and colleagues, these cells look like an intermediate between the N and S types
via diverse measures including phase contrast microscopy, intermediate filament expression,
tyrosine hydroxylase activity, and norepinephrine uptake [64]. Consistent with being a tumor
stem-like cell (or tumor initiating cell), I-type cells are by far the most tumorigenic in mice and
in in vitro surrogate assays of tumor formation. Treatment with 13-cis retinoic acid or 5-
bromo-2’-deoxyuridine can differentiate I-type cells into N-type or S-type, respectively.
Retinoic acid has significant effects on integrins, consistent with changes seen during neuronal
differentiation, and can differentiate some neuroblastomas into a benign growth-arrested state
[67]. Clinically, retinoic acid has also been demonstrated to improve event free and overall
survival in a long-term follow-up on a large cohort of neuroblastoma patients [68].
4. Signaling by integrins
In addition to key roles in cell anchorage and migration, integrin-mediated ligation of the
extracellular matrix results in the initiation of signaling events exerting both local and cellular
effects. Thus, the extracellular matrix encodes information via the local milieu of cell surface
or diffusible factors presented to the cell (Figure 4). Most of these signals have been studied in
rigorously defined systems in vitro with cell lines, rather than primary in vivo investigation.
4.1. Integrin ligation promotes the activation of the nonreceptor tyrosine kinases FAK and
Src
Signaling that follows the ligation of integrins by extracellular matrix components can be
studied by introducing suspended neuroblastoma cells to a surface coated with an extracellular
matrix component, such as fibronectin. This results in cell attachment and spreading. Con‐
current with these events, phosphorylation is observed on cytosolic nonreceptor tyrosine
kinases like FAK (tyrosine residue 397) and Src (tyrosine residue 418), which indicate activation
of the tyrosine kinases. At least some of this activity is physically present in the integrin
associated focal adhesion complex, and these kinases can be co-purified with integrins from
this complex.
FAK and Src can associate with each other and with an array of cytosolic adaptor proteins and
other effectors. For example, FAK can associate with the cytoskeletal adaptor protein talin,
which also binds to integrins. The adhesion of NB7 neuroblastoma cells to fibronectin or
collagen has been shown to promote co-association of these molecules together in a complex
with the protease calpain. Calpain in turn cleaves talin in a cell-adhesion dependent manner,
which faciliates more rapid turn over of the focal adhesion, and promotes neuroblastoma cell
migration. The same cleavage is observed in other neuroblastoma cells, including NB5 and
NB16, suggesting it may be a conserved pathway [69].
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FAK also associates with Grb2 and SoS [70], key regulators of Ras-GTP mediated activation of
the Raf/MEK/ERK pathway of MAP kinase signaling. This pathway helps to drive proliferation
of the tumor cells, and may account for adhesion-based induction of cyclin E in neuroblastoma
(and other) cells [71]. FAK is perhaps best known for its capacity to support and promote
integrin-mediated cell migration on an ECM, and performs this function in neuroblastoma
cells as well, although this appears to be integrin specific [61]. For example, integrin α5β1
activates FAK and uses this kinase for migration, while integrin α4β1 migration is dependent
upon the non-receptor kinase Src. Both integrins can bind to a fibronectin substrate, thus the
particular integrin ligated can have an impact on the cells' response. Other effects of specific
integrin ligation have been reported in non-neuroblastoma cell lines, such as the FAK and
α5β1-induced expression of the pro-survival gene Bcl-2 [72]. Thus, signals from FAK can play
a role in regulating cell survival in an ECM and integrin-dependent manner.
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Figure 4. Signaling Pathways Downstream of Integrins The continued survival of a single cell and its progeny in the
wrong environment can disrupt the homeostasis of the tissue that contains them. Thus, the impetus of individual cells
to live or die is critical for the continued homeostasis of an organism. Recognition of compatible ECM promotes stable
ligation and clustering of integrins, as well as assembly of the heterogeneous and dynamic focal adhesion complex.
Signaling from integrins and focal adhesion-associated receptor tyrosine kinases (RTK) leads to downstream pro-sur‐
vival signaling pathways such as the PI3K /AKT and Erk axes. By contrast, the presence of an incompatible ECM or of
unligated or antagonized integrins promotes cell death via anoikis pathways, including integrin-mediated death. N-
Myc exerts pleiotropic effects via transcription (or inhibition thereof) of many downstream genes, enhancing prolifera‐
tion and survival, and attenuating the expression of integrins, and therefore decreasing anoikis signaling.
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4.2. Integrin activation of the phosphoinositide 3’ kinase signaling axis
Integrins stabilized and ligated to correct ECM promote signaling via class I phosphoinisotol-3
kinases (PI3K). PI3K’s are a family of lipid bound kinases found at the cell membrane or
intracellular endosomes, and can promote cell motility, intracellular trafficking and survival.
Among the four class I PI3K’s, neuroblastoma tend to express P110α and p110β, with the latter
more likely to be associated with N-Myc expressing tumors. Nonetheless, P110γ and p110δ
are also sometimes detected [73]. Activation of the PI3K signaling axis promotes malignancy
in numerous cancer cell lines and models of human cancer [74]. PI3K signaling also enhances
turnover of pro-mitochondrial apoptotic proteins like Bad and promotes downstream pro-
survival pathways, such as AKT and mTOR [75]. PTEN, a suppressor of PI3K, is frequently
lost in cancer, although studies in neuroblastoma have shown a lesser degrees of loss, in the
range of ~5% for homozygous deletion [76]. Mutations of PI3K that enhance kinase activity
have been reported in other cancers [77], yet they have been proven to be infrequent in
neuroblastoma [78]. Thus, the activity of PI3K appears to frequently depend upon extrinsic
regulatory factors, mediated by receptor tyrosine kinases (eg., IGFR-1, ALK) and integrins.
Given the lack of effective therapies for malignant neuroblastoma, it is perhaps not surprising
that the PI3K pathway is being pursued for pharmacological intervention [79]. In neuroblas‐
toma, inhibition of PI3K has been demonstrated to decrease migration and survival of tumor
cells in vitro, and inhibit tumor growth in vivo [80, 81]. The efficacy of pharmacological PI3K
inhibition may be enhanced by combining a pro-drug with an RGDS peptide to target the agent
to tumor sites [81]. The relative affinity for this linear peptide for integrin, however, is quite
low, and it is improbable that enhanced efficacy is due to direct action on integrins, rather, it
is likely due to improved pharmacokinetics associated with the targeting peptide.
4.3. Interplay between integrins and signature neuroblastoma signaling pathways
N-Myc is a transcription factor normally expressed during early lymphocyte development and
in embryonic brain and kidney tissues [82], and is critical for survival of neural crest-derived
neurons [83]. Amplification of greater than ten copies of the MYCN gene has long been
recognized as a strong negative prognostic indicator of outcome in neuroblastoma [84]. N-Myc
interacts with integrins in an antagonistic manner; while N-Myc seems to increase expression
of FAK, it has also been shown to down-regulate the expression of integrins such as α3β1 and
α1β1 [85-88]. Transcriptional analysis of the β3 and αv promoters have revealed negative
transcriptional regulatory elements in their promoters by the closely related c-Myc [76],
suggesting why αvβ3 is not highly expressed in neuroblastoma relative to other tumors. In
fact, the loss of integrin expression may be important for survival in specific circumstances,
particularly among tumors that retain intrinsic apoptotic capacity, as discussed below.
ALK is a tyrosine kinase that is expressed largely during development within the nervous
system. ALK belongs to the ‘insulin-like tyrosine kinase’ family of receptors that is frequently
upregulated or subject to oncogenic mutation in neuroblastoma [89]. Signaling by tyrosine
kinases generally requires integrin ligation [5], activating downstream targets (such as FAK,
Src, PI3K etc.). This suggests that there is an intrinsic requirement for ECM adhesion to permit
a tumor to ‘leverage’ amplified ALK. However, mutant forms of ALK also exist, particularly
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a F1174 mutation that drives neuroblastoma malignancy cooperatively with MYCN. In this
case, it is unclear whether integrin-mediated adhesion is actually required for cell proliferation,
although it is likely to enhance signaling in keeping with the rationale described above. MYCN
also leads to increased expression of a close ALK relative, insulin-like growth factor I receptor
(IGF-IR). In this case, crosstalk between IGF-IR and integrins is also observed [90].
4.4. Integrins and cell survival signaling
Cells that lose anchorage for extended periods of time will typically undergo apoptosis. This
phenomenon encompasses one aspect of anoikis (gr., homelessness), a phenomenon wherein
a cell that finds itself in an inappropriate environment is signaled to undergo apoptosis.
However, there is no ‘central cell death pathway’ associated with anoikis, and in fact many
different pathways have been validated in the literature. This underscores the critical need for
cell adhesion. One anoikis pathway is focused on the activation of caspase-9. Although many
neuroblastomas lose expression of one copy of caspase-9 (as many are LOH1p21), this does
not appear to impact the capacity of caspase-9 to activate [91]. Antagonism of b1 integrins on
differentiated neuroblastoma, but not undifferentiated, promotes this apoptotic pathway [92].
Integrin-mediated death is an anoikis pathway in which the presence of unligated, or antago‐
nized, integrins on the cell surface promote cell death via the activation of caspase-8. Neuroblas‐
toma avoid this death pathway via several mechanisms. First, the amplification of MYCN can
lead to an overall decrease in integrin expression, which lowers the capacity of the pathway to
trigger. Secondly, stage III and IV neuroblastoma tend to methylate, delete, or disrupt the
caspase-8 gene [93, 94], preventing the triggering of the apoptotic pathway, and this results in a
survival advantage in vitro and a metastasis advantage in vivo. Finally, neuroblastoma that are
seeded as individual cells in an ‘inappropriate’ three dimensional matrix will tend to either die
or, within only a couple days, find each other and form small cell clusters. These islands of cells
promote their own survival and can persist, although they are sometimes surrounded by
apoptotic bodies as errant progeny try to migrate away from the original cell mass.
Opposing the induction of death by unligated or antagonized integrins, it is worth noting that
a cell that has a robust interaction with the ECM is more resistant to certain insults than others,
and integrin ligation has been linked to chemo and radiation resistance. Mechanistically, this
is likely to result from remodeling of the ECM, combined with transcriptional alterations of
survival promoting genes such as Bcl-2 family members, IAPs and others. However, direct
effects, such as maturation-inhibiting phosphorylation of procaspase-8, cannot be excluded
from contributing to this effect [95, 96].
5. Specific integrins in neuroblastoma progression
5.1. Integrin αvβ3
Integrin αvβ3 is the most ‘promiscuous’ member of the integrin family, in that it binds a variety
of different RGD conformations, and thus binds to ligands that include vitronectin, fibronectin,
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fibrinogen, von Willebrand factor and others. Gladson et al. found that αv was present in all
tumors they examined regardless of stage. While αvβ1 and αvβ5 heterodimers were found in
normal adrenal tissues and ganglioneuroblastomas which exhibit lower levels of dissemina‐
tion, the αvβ3 integrin was found to be expressed in highly metastatic, undifferentiated
neuroblastomas [62]. By contrast, we observe only very low levels of integrin αvβ3 on our
neuroblastoma specimens relative to melanoma or cultured endothelial cells, which express
robust levels of αvβ3. However, it remains possible that the techniques originally used by
Gladson were simply very sensitive and detected this modest but important level of integrin
expression. Indeed, αvβ3 is, in some systems, a stem cell marker, and this may reflect the
advanced stage and poor prognosis of her positive cohort.
In addition, on a variety of tumor cells, αvβ3 expression has been demonstrated to promote
tumor progression by its ability to bind to a wide array of different ligands, facilitating
anchorage and invasion. Integrin αvβ3 also stimulates MMP activity, promotes the activation
of receptor and non-receptor tyrosine kinases including src, and the release of growth factors
such as TGF that promote tumor response. This vascularization provides the growing tumor
with the nutrients it needs and brings tumor cells proximal to vessels, which may facilitate
invasion and metastasis. As previously mentioned, αvβ3 is also expressed on angiogenic
endothelial cells where it promotes cell survival and migration. One study showed that there
is higher β3 expression on invasive and metastatic melanomas than on noninvasive melanomas
[97], although the levels demonstrated in these cases appear to be logarithmically higher than
those seen on neuroblastoma cell lines [98].
5.2. Integrin α4β1 and tumor spread
Integrin α4β1 is primarily known as a trafficking integrin, as it is present on most leukocytes.
Binding to its ligand VCAM-1, present on activated endothelial cells, enhances the transen‐
dothelial migration of white blood cells into surrounding tissues. Cancer cells that express
α4β1 acquire this same enhanced trafficking potential and show increased tumor cell arrest in
circulation and increased extravasation and colony formation. α4β1 may also enhance invasion
and metastasis through promotion of angiogenesis and lymphangiogenesis [99, 100]. In [97],
α4β1 expression was found on 40% of invasive and metastatic melanomas, although not on
non-malignant melanocytes.
It is important to note that, though the expression of α4β1 can indeed promote extravasation,
the overall role of integrin α4β1 in tumor progression and metastasis is highly controversial
and is dependent on the level of expression and the phase of tumor progression. For example,
high α4β1 expression in some primary tumors can enhance homotypic cell-cell adhesion [101],
preventing cells from breaking away from the tumor and invading into surrounding tissues
[102]. In addition, α4β1 expression can lead to a reduction in MMPs and impair the ability of
the cells to degrade the matrix and create a pathway for invasion [103]. If cells do successfully
metastasize to distant sites, α4β1 expression may promote or inhibit metastatic growth
depending on the microenvironment.
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6. Drugs that target integrins
The involvement of integrins in multiple stages of tumor progression makes them attractive
therapeutic targets. Inhibition of integrin signaling can be achieved using several approaches
including blocking ligand binding, preventing the formation of functional focal adhesion
complexes and disrupting integrin association with the cytoskeleton. Because the structure of
integrins has been extensively studied and because having an extracellular target eliminates
the challenges of intracellular delivery, the most common approach has been to target the
integrin ligand-binding site. This has been accomplished using blocking antibodies, cyclic and
ligand-mimicking peptides, small molecule antagonists and disintegrins [104] (Table 2).
Target Antagonist Type Clinical Development
αvβ3 Vitaxin humanized antibody Phase II trials
CNTO 95 humanized antibody Phase II trials
c7E3
(Abciximab)
Chimeric mouse- human
antibody
FDA approved (1994) for use in
percutaneous coronary
intervention (PCI)
Cilengitide cyclic peptide Phase III trials for glioblastoma
multiforme; Phase II trials for
melanoma, glioma, and SCCHN;
Phase I trials for NSCLC
L000845704 Small molecule Phase I trials
SB273005 Small molecule Pre-clinical animal studies
α4β1 Natalizumab humanized antibody FDA approved (1994) for
treatment of multiple sclerosis
and Crohn’s disease
MLN-00002 human antibody Phase II trials
Firategrast small molecule Phase II trials
αIIbβ3 c7E3 (Abciximab) Chimeric mouse- human
antibody
FDA approved (1994) for use in
percutaneous coronary
intervention (PCI)
Eptifibatide cyclic peptide FDA approved (1998) for use in
patients with acute coronary
syndrome or undergoing PCI
Tirofiban small molecule FDA approved in 1999
α5β1 Volociximab chimeric human-mouse
antibody
Phase II trials in melanoma,
pancreatic cancer, and NSCLC
JSM6427 small molecule Phase I trials
α2β1 Rhodocetin disintegrin Pre-clinical
Table 2. Drugs that Target Integrins
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6.1. Integrin αv
The primary rationale for targeting integrin αvβ3 in cancer is to reduce primary tumor growth
and metastasis via nutrient deprivation due to inhibition of tumor angiogenesis. Several αvβ3
antagonists have gone to clinical trials with the most notable being cilengitide. Cilengitide is
a cyclic peptide containing the RGD integrin-binding motif. It inhibits both αvβ3 and αvβ5.
Cilengitide produces both anti-angiogenic and anti-tumor effects through inhibition of VEGF
stimulation and FAK-Src and Erk signaling, respectively [105]. In vitro, cilengitide reduces cell
growth and survival and inhibits endothelial and tumor cell migration. In clinical trials,
cilengitide has been evaluated as a single agent and in combination with radiation, DNA-
alkylating agents and gemcitibine. Importantly, cilengitide in combination with radiotherapy
and temozolomide (a DNA-alkylating agent) has reached phase III trials in glioblastoma
multiforme patients. Other small molecule antagonists are in development for noncancer
indications.
6.2. Integrin α4
The integrin α4 subunit is predominantly expressed in lymphocytes and leukocytes and
supports endothelial transmigration of these cells via binding to VCAM-1. Consequently, α4
is important for immune function and has been targeted in diseases such as multiple sclerosis
(MS), Crohn’s disease and asthma that are characterized by excessive inflammation or an
improper immune response. Natalizumab, the only FDA approved α4 antagonist, is a
humanized mouse monoclonal antibody that binds both α4 heterodimers. The use of natali‐
zumab was successful in clinical trials in MS [106, 107] and Crohn’s disease [108] with the
exception of rare cases of progressive multi-focal leukoencephalopathy (PML) caused by
reactivation of latent JC virus associated with immunosuppression [109]. Unfortunately, this
side effect was detrimental enough to lead to limitation of the use of natalizumab to patients
who are unresponsive to other treatments. Other α4 antagonists under clinical evaluation
include MLN-00002 (human α4β7 antibody), firategrast and IVL745 (small molecules: [104]).
Though the rationale for the use of most α4 antagonists is to reduce excessive infiltration of
immune cells, these therapies have the potential for use against cancer cells that exploit α4 for
tumor cell extravasation. The success of targeting α4 in cancer will depend on the ability to
minimize immunosuppression or to indirectly impair α4 function via downstream targets.
6.3. Integrin αIIbβ3
Integrin αIIbβ3 is also a frequently targeted integrin. This heterodimer is expressed selectively
on platelets and megakaryocytes and is mostly known for its role in blood coagulation.
Antagonists of this receptor are primarily employed in diseases such as stroke, sickle cell
anemia and acute coronary syndromes [104].
7. Summary and considerations
Integrins are a unique group of receptors that provide anchorage, mediate cell migration
and  invasion,  and  signal  via  cell  survival  and  proliferation  pathways.  Aptly  named,
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integrins integrate extracellular cues with intracellular signaling and serve to regulate many
cellular processes that are mediated by other receptors, such as receptor tyrosine kinases.
The importance of integrins in cancer development of the nervous system is well establish‐
ed;  it  seems inevitable  therefore  that  they  play  a  major  role  in  neuroblastoma progres‐
sion. In fact, integrin expression has been linked to malignancy in neuroblastoma, possibly
due  to  alterations  in  invasiveness  and  the  ability  to  evade  cell  death  in  foreign  tissue
environments. Aggressive disease may modulate integrin expression (i.e. N-Myc).
Targeting integrins has shown great clinical promise. By inhibiting ligand binding, many
antagonists successfully disrupt cellular connections to the extracellular environment and pro-
survival pathways that are necessary for tumor progression. As we continue to learn more
about the downstream signaling activity of integrin receptors, we can also explore more
therapeutic avenues against these targets, attacking the problem from both sides. However,
the logical use of integrin antagonists in complex, multi-agent regimens is lacking. Given the
synergy of integrins with signaling through receptor tyrosine kinases and in the induction of
susceptibility to apoptosis, this is where one would suspect that these relatively non-toxic
agents would have their greatest impact.
Though clinical studies of integrin-targeted drugs in neuroblastoma have not been performed,
in vitro antagonism has been shown to decrease cell survival, migration and invasion. Despite
these characteristics, integrin-targeted drugs are well tolerated. Given that current treatment
for neuroblastoma still has a significant failure rate, the addition of new, low toxicity adjuncts
to current treatment regimens seems a logical step forward. In the future, an increased
understanding of the roles of specific integrins in neuroblastoma has the potential to provide
better prognostic information regarding disease course, while targeting integrins, perhaps in
combination with other targeted therapies as a cocktail addition to standard chemotherapy
approaches, may lead to increased effectiveness in managing this disease.
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